BioDrugs

, Volume 9, Issue 1, pp 1–10 | Cite as

Therapeutic Ribozymes

Principles and Applications
Leading Article

Summary

Ribozymes have progressed from an intriguing subject of scientific study to therapeutic agents for the potential treatment of both acquired and inherited diseases. Clinical trials using ribozymes targeted against HIV, the aetiological agent of AIDS, have recently been initiated. Despite this rapid progression to clinical application, there are many unexplored avenues which still must be examined to improve the intracellular effectiveness of ribozymes. Since ribozymes are RNA molecules which selectively cleave RNA targets via base-pairing interactions, the rules governing nucleic acid hybridisation affect ribozyme function. In addition, knowledge of the cellular mechanisms governing RNA partitioning and stability apply equally to ribozymes as they do to the target RNAs. The successful therapeutic application of ribozymes depends upon increasing our knowledge of RNA metabolism and movement, and applying this knowledge in the design of ribozymes. This review summarises some of the progress and experimental approaches towards achieving these goals as well as surveying experimental testing of potential therapeutic applications. It is becoming increasingly evident that ribozymes can serve the dual function of a tool to elucidate the functional roles of many gene products as well as a therapeutic agent designed to functionally destroy deleterious RNAs.

Keywords

Adis International Limited Long Terminal Repeat Hepatitis Delta Virus Hammerhead Ribozyme Hairpin Ribozyme 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Krager K, Grabowski PJ, Zaug AJ, et al. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982; 31: 147–57CrossRefGoogle Scholar
  2. 2.
    Guerrier-Takada C, Gardiner K, Marsh T, et al. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 1983; 35: 849–57PubMedCrossRefGoogle Scholar
  3. 3.
    Cech TR. Ribozyme engineering. Curr Opin Struct Biol 1992; 2: 605–9CrossRefGoogle Scholar
  4. 4.
    Rossi JJ. Making ribozymes work in cells. Curr Biol 1994; 4: 469–71PubMedCrossRefGoogle Scholar
  5. 5.
    Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature 1992; 371: 619–22CrossRefGoogle Scholar
  6. 6.
    Young B, Herschlag D, Cech TR. Mutations in a nonconserved sequence of the Tetrahymena ribozyme increase activity and specificity. Cell 1991; 29: 10159–71Google Scholar
  7. 7.
    Dahm SC, Derrick WB, Uhlenbeck OC. Evidence for the role of solvated metal hydroxide in the hammerhead cleavage mechanism. Biochemistry 1993; 32: 13040–5PubMedCrossRefGoogle Scholar
  8. 8.
    Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 1990; 29: 10695–702PubMedCrossRefGoogle Scholar
  9. 9.
    Goodchild J, Kohli V. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate. Arch Biochem Biophys 1991; 284: 386–91PubMedCrossRefGoogle Scholar
  10. 10.
    Hendry P, McCall MJ, Santiago FS, et al. A ribozyme with DNA in the hybridising arms displays enhanced cleavage ability. Nucleic Acids Res 1992; 20: 5737–41PubMedCrossRefGoogle Scholar
  11. 11.
    Paolella G, Sproat BS, Lamond AI. Nuclease resistant ribozymes with high catalytic activity. EMBO J 1992; 11: 1913–9PubMedGoogle Scholar
  12. 12.
    Taylor NR, Kaplan BE, Swiderski P, et al. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res 1992; 20: 4559–65PubMedCrossRefGoogle Scholar
  13. 13.
    Bratty J, Chartrand P, Ferbeyre G, et al. The hammerhead RNA domain, a model ribozyme. Biochim Biophys Acta 1993; 1216: 345–9PubMedCrossRefGoogle Scholar
  14. 14.
    Heidenreich O, Benseier P, Fahrenholz A, et al. High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates. J Biol Chem 1994; 269: 2131–8PubMedGoogle Scholar
  15. 15.
    Jarvis TC, Wincott FE, Laverna JA, et al. Optimizing the cell efficacy of synthetic ribozymes: site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J Biol Chem 1996; 271: 29107–12PubMedCrossRefGoogle Scholar
  16. 16.
    Hertel KJ, Herschlag D, Uhlenbeck OC. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry 1994; 33: 3374–85PubMedCrossRefGoogle Scholar
  17. 17.
    Hertel KJ, Uhlenbeck OC. The internal equilibrium of the hammerhead ribozyme reaction. Biochemistry 1995; 34: 1744–9PubMedCrossRefGoogle Scholar
  18. 18.
    Dropulic B, Lin NH, Martin MA, et al. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J Virol 1992; 66: 1432–41PubMedGoogle Scholar
  19. 19.
    Dropulic B, Jeang KT. A virus model for examining the intracellular efficiency of a ribozyme targeted to HIV-1. Methods: a Companion to Methods in Enzymology 1993; 5: 43–9CrossRefGoogle Scholar
  20. 20.
    Xing Z, Whitton JL. An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield. J Virol 1993; 67: 1840–7PubMedGoogle Scholar
  21. 21.
    Bertrand E, Pictet R, Frange T. Can hammerhead ribozymes be efficient tools to inactivate gene function? [published erratum appears in Nucleic Acids Res 1994 Apr 11; 22 (7): 1326]. Nucleic Acids Res 1994; 22: 293–300PubMedCrossRefGoogle Scholar
  22. 22.
    Sullenger B, Cech TR. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 1993; 262: 1566–9PubMedCrossRefGoogle Scholar
  23. 23.
    Cameron FH, Jennings PA. Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci USA 1989; 86: 9139–43PubMedCrossRefGoogle Scholar
  24. 24.
    Steinecke P, Herget T, Schreier PH. Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo. EMBO J 1992; 11: 1525–30PubMedGoogle Scholar
  25. 25.
    Zhao JJ, Pick L. Generating loss-of-function phenotypes of the fushi tarazu gene with a targeted ribozyme in Drosophila. Nature 1993; 365: 448–51PubMedCrossRefGoogle Scholar
  26. 26.
    Efrat S, Fusco-DeMane M, Wu Y-J, et al. Ribozyme-mediated attenuation of pancreatic beta-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion. Proc Natl Acad Sci USA 1994; 91: 2051–5PubMedCrossRefGoogle Scholar
  27. 27.
    Larsson S, Hotchkiss G, Andang M, et al. Reduced β2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res 1994; 22: 2242–8PubMedCrossRefGoogle Scholar
  28. 28.
    Sarver N, Cantin EM, Chang PS, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990; 247: 1222–5PubMedCrossRefGoogle Scholar
  29. 29.
    Zhou C, Bahner IC, Larson GP, et al. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994; 149: 33–9PubMedCrossRefGoogle Scholar
  30. 30.
    Bauer G, Valdez P, Kearns K, et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 1997; 89(7): 2259–67PubMedGoogle Scholar
  31. 31.
    Chen CJ, Banerjea AC, Harmison GG, et al. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication: potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 1992; 20: 4581–9PubMedCrossRefGoogle Scholar
  32. 32.
    Crisell P, Thompson S, James W. Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro. Nucleic Acids Res 1993; 21: 5251–5PubMedCrossRefGoogle Scholar
  33. 33.
    Dropulic B, Hermankova M, Pitha PM. A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci USA 1996; 93: 11103–8PubMedCrossRefGoogle Scholar
  34. 34.
    Lo KM, Biasolo MA, Dehni G, et al. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 1992; 190: 176–83PubMedCrossRefGoogle Scholar
  35. 35.
    Ojwang JO, Hampel A, Looney DJ, et al. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 1992; 89: 10802–6PubMedCrossRefGoogle Scholar
  36. 36.
    Weerasinghe M, Liem SE, Asad S, et al. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991; 65: 5531–4PubMedGoogle Scholar
  37. 37.
    Yamada O, Yu M, Yee JK, et al. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther 1994; 1: 38–45PubMedGoogle Scholar
  38. 38.
    Yu M, Ojwang J, Yamada O, et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1 [published erratum appears in Proc Natl Acad Sci USA 1993 Sep 1; 90 (17): 8303]. Proc Natl Acad Sci USA 1993; 90: 6340–4PubMedCrossRefGoogle Scholar
  39. 39.
    Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213–22PubMedCrossRefGoogle Scholar
  40. 40.
    Lieber A, He CY, Polyak SJ, et al. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996; 70: 8782–91PubMedGoogle Scholar
  41. 41.
    Koizumi M, Kamiya H, Ohtsuka E. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene 1992; 117: 179–84PubMedCrossRefGoogle Scholar
  42. 42.
    Li M, Lonial H, Citarella R, et al. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther 1996; 3: 221–9PubMedGoogle Scholar
  43. 43.
    Snyder DS, Wu Y, Wang JL, et al. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 1993; 82: 600–5PubMedGoogle Scholar
  44. 44.
    Shore SK, Nabissa PM, Reddy ER Ribozyme-mediated cleavage of the BCR-ABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oncogene 1993; 8: 3183–8PubMedGoogle Scholar
  45. 45.
    Daly C, Coyle S, McBride S, et al. mdrl ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines. Cytotechnology 1996; 19: 199–205PubMedCrossRefGoogle Scholar
  46. 46.
    Czubayko F, Schulte AM, Berchem GJ, et al. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 1996: 93: 14753–8PubMedCrossRefGoogle Scholar
  47. 47.
    Kanazawa Y, Ohkawa K, Ueda K, et al. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 1996; 225: 570–6PubMedCrossRefGoogle Scholar
  48. 48.
    Kilpatrick MW, Phylactou LA, Godfrey M, et al. Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts. Hum Mol Genet 1966; 5: 1939–44CrossRefGoogle Scholar
  49. 49.
    Sioud M. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by peritoneal cells in vitro and in vivo. Eur J Immunol 1996; 26: 1026–31PubMedCrossRefGoogle Scholar
  50. 50.
    Turck J, Pollock AS, Lee LK, et al. Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 1996; 271: 15074–83PubMedCrossRefGoogle Scholar
  51. 51.
    Jarvis TC, Alby LJ, Beaudry AA, et al. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. RNA 1996; 2: 419–28PubMedGoogle Scholar
  52. 52.
    Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62: 191–217PubMedCrossRefGoogle Scholar
  53. 53.
    Muzcyzka N. Curr Top Microbiol Immunol 1992; 158: 7–123Google Scholar
  54. 54.
    Bertrand EL, Rossi JJ. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J 1994; 13: 2904–12PubMedGoogle Scholar
  55. 55.
    Herschlag D, Khosla M, Tsuchihashi Z, et al. An RNA chaper-one activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis [published erratum appears in EMBO J 1994 Aug 15; 13(16): 3926]. EMBO J 1994; 13: 2913–24PubMedGoogle Scholar
  56. 56.
    Tsuchihashi Z, Khoslo M, Herschlag D. Protein enhancement of hammerhead ribozyme catalysis. Science 1993; 262: 99–102PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Department of Molecular BiologyBeckman Research Institute of the City of HopeDuarteUSA

Personalised recommendations